Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant

References

• Frassoni F. Anti-T-cell globulin: an essential ingredient for haematopoietic cell transplantation? Lancet Oncol 2009;10:839.
   PubMed Web of Science ®Google Scholar
• Brayman K. New insights into the mechanisms of action of thymoglobulin. Transplantation 2007;84:S3–S4.
   Google Scholar
• Zand MS, Vo T, Pellegrin T, . Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 2006;107:2895–2903.
   PubMed Web of Science ®Google Scholar
• Zand MS, Vo T, Huggins J, . Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005;79:1507–1515.
   PubMed Web of Science ®Google Scholar
• Lowsky R. Thymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation. Transplantation 2007;84: S20–S26.
   PubMedGoogle Scholar
• Finke J, Bethge WA, Schmoor C, . Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10:855–864.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, . Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942–2947.
   PubMed Web of Science ®Google Scholar
• Champlin RE, Perez WS, Passweg JR, . Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007;109:4582–4585.
   PubMed Web of Science ®Google Scholar
• Remberger M, Svahn BM, Mattsson J, . Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004;78:122–127.
   PubMed Web of Science ®Google Scholar
• Seidel MG, Fritsch G, Matthes-Martin S, . Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005;27: 532–536.
   PubMed Web of Science ®Google Scholar
• Parmar S, Del Lima M, Zou Y, . Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 2009;114:2884–2887.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Khouri I, Ippoliti C, . Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999;24:763–768.
   PubMed Web of Science ®Google Scholar
• Berry DA, Eick SG. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med 1995;14:231–246.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Deeg HJ, Storer BE, Boeckh M, . Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006;12:573–584.
   PubMed Web of Science ®Google Scholar
• Schattenberg A, van der Meer A, Preijers F, . Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplant 2004;33:1115–1121.
   PubMed Web of Science ®Google Scholar
• Basara N, Baurmann H, Kolbe K, . Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005;35:1011–1018.
   PubMed Web of Science ®Google Scholar
• Remberger M, Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005;90:931–938.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Milone G, . Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day + 7 after alternative donor transplants. Bone Marrow Transplant 2010;45:385–391.
   PubMed Web of Science ®Google Scholar
• Podgorny PJ, Ugarte-Torres A, Liu Y, . High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 2010;16:915–926.
   PubMed Web of Science ®Google Scholar
• Remberger M, Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 2009;15:996–999.
   PubMed Web of Science ®Google Scholar